25 XP   0   0   10

Rekah Pharmaceutical Industry Ltd
Buy, Hold or Sell?

Let's analyse Rekah together

PenkeI guess you are interested in Rekah Pharmaceutical Industry Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Rekah Pharmaceutical Industry Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Rekah Pharmaceutical Industry Ltd

I send you an email if I find something interesting about Rekah Pharmaceutical Industry Ltd.

Quick analysis of Rekah (30 sec.)










What can you expect buying and holding a share of Rekah? (30 sec.)

How much money do you get?

How much money do you get?
ILA0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
ILA13.71
Expected worth in 1 year
ILA13.02
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
ILA-0.69
Return On Investment
-0.1%

For what price can you sell your share?

Current Price per Share
ILA1,367.00
Expected price per share
ILA1,326 - ILA1,507
How sure are you?
50%

1. Valuation of Rekah (5 min.)




Live pricePrice per Share (EOD)

ILA1,367.00

Intrinsic Value Per Share

ILA7,080.53 - ILA8,454.13

Total Value Per Share

ILA7,094.24 - ILA8,467.83

2. Growth of Rekah (5 min.)




Is Rekah growing?

Current yearPrevious yearGrowGrow %
How rich?$425.5k$452.3k-$14.9k-3.4%

How much money is Rekah making?

Current yearPrevious yearGrowGrow %
Making money-$573.7k$251.9k-$825.6k-143.9%
Net Profit Margin-2.7%1.2%--

How much money comes from the company's main activities?

3. Financial Health of Rekah (5 min.)




What can you expect buying and holding a share of Rekah? (5 min.)

Welcome investor! Rekah's management wants to use your money to grow the business. In return you get a share of Rekah.

What can you expect buying and holding a share of Rekah?

First you should know what it really means to hold a share of Rekah. And how you can make/lose money.

Speculation

The Price per Share of Rekah is ILA1,367. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rekah.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rekah, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ILA13.71. Based on the TTM, the Book Value Change Per Share is ILA-0.17 per quarter. Based on the YOY, the Book Value Change Per Share is ILA-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ILA0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rekah.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per ShareILA% of Price per Share
Usd Eps-0.130.0%-0.030.0%0.020.0%0.020.0%0.000.0%
Usd Book Value Change Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.180.0%0.050.0%0.020.0%
Usd Total Gains Per Share0.000.0%0.000.0%0.180.0%0.050.0%0.020.0%
Usd Price Per Share4.86-4.43-5.77-5.85-5.92-
Price to Earnings Ratio-9.29-25.22-41.52-78.37-50.75-
Price-to-Total Gains Ratio-3,792.86--1,716.34-8,415.06-6,381.01-6,062.06-
Price to Book Ratio130.44-115.80-145.45-152.44-190.13-
Price-to-Total Gains Ratio-3,792.86--1,716.34-8,415.06-6,381.01-6,062.06-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.71824
Number of shares268
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.05
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.05
Gains per Quarter (268 shares)-0.1312.79
Gains per Year (268 shares)-0.5051.16
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1-1151041
20-1-12102092
30-2-131530143
40-2-142040194
50-3-152550245
60-3-163070296
70-4-173580347
80-4-184091398
90-5-194601449
100-5-205111500

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%9.03.00.075.0%16.04.00.080.0%26.09.05.065.0%57.09.014.071.3%
Book Value Change Per Share1.03.00.025.0%7.05.00.058.3%14.06.00.070.0%26.014.00.065.0%55.025.00.068.8%
Dividend per Share0.00.04.00.0%4.00.08.033.3%4.00.016.020.0%4.00.036.010.0%10.00.070.012.5%
Total Gains per Share1.03.00.025.0%9.03.00.075.0%16.04.00.080.0%28.012.00.070.0%58.022.00.072.5%

Fundamentals of Rekah

About Rekah Pharmaceutical Industry Ltd

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company offers steroid tablets; antibiotics, including penicillin and cephalosporin; drops and ointments to treat allergies, infections, and dryness of the eyes; baby products; and dermatological preparations. Its portfolio of products comprise approximately 280 drugs used in various medical fields. Rekah Pharmaceutical Industry Ltd. was founded in 1941 and is based in Holon, Israel.

Fundamental data was last updated by Penke on 2024-03-12 15:38:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Rekah Pharmaceutical Industry Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Rekah earns for each 1 of revenue.

  • Above 10% is considered healthy but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -6.9% means that -0.07 for each 1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is -6.9%. The company is making a loss. -1
  • The TTM is -2.7%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-6.9%TTM-2.7%-4.2%
TTM-2.7%YOY1.2%-3.9%
TTM-2.7%5Y1.2%-3.9%
5Y1.2%10Y0.0%+1.2%
1.1.2. Return on Assets

Shows how efficient Rekah is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • -116.6% Return on Assets means that Rekah generated -1.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is -116.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -45.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-116.6%TTM-45.0%-71.6%
TTM-45.0%YOY21.3%-66.2%
TTM-45.0%5Y18.8%-63.8%
5Y18.8%10Y0.9%+17.9%
1.1.3. Return on Equity

Shows how efficient Rekah is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • -351.1% Return on Equity means Rekah generated -3.51 for each 1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is -351.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -133.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-351.1%TTM-133.3%-217.8%
TTM-133.3%YOY53.8%-187.1%
TTM-133.3%5Y41.3%-174.6%
5Y41.3%10Y-4.8%+46.1%

1.2. Operating Efficiency of Rekah Pharmaceutical Industry Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rekah is operating .

  • Measures how much profit Rekah makes for each 1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated 0.00  for each 1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1.7%-1.7%
TTM1.7%YOY5.1%-3.5%
TTM1.7%5Y7.1%-5.4%
5Y7.1%10Y4.7%+2.4%
1.2.2. Operating Ratio

Measures how efficient Rekah is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.79 means that the operating costs are 1.79 for each 1 in net sales.

Let's take a look of the Operating Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is 1.786. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.720. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.786TTM1.720+0.065
TTM1.720YOY1.670+0.050
TTM1.7205Y1.677+0.044
5Y1.67710Y1.313+0.364

1.3. Liquidity of Rekah Pharmaceutical Industry Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rekah is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.68 means the company has 1.68 in assets for each 1 in short-term debts.

Let's take a look of the Current Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is 1.684. The company is able to pay all its short-term debts. +1
  • The TTM is 1.741. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.684TTM1.741-0.057
TTM1.741YOY2.031-0.290
TTM1.7415Y2.067-0.326
5Y2.06710Y1.528+0.540
1.3.2. Quick Ratio

Measures if Rekah is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.83 means the company can pay off 0.83 for each 1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is 0.831. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.891. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.831TTM0.891-0.060
TTM0.891YOY1.031-0.140
TTM0.8915Y0.933-0.042
5Y0.93310Y0.975-0.041

1.4. Solvency of Rekah Pharmaceutical Industry Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rekah assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rekah to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.67 means that Rekah assets are financed with 66.8% credit (debt) and the remaining percentage (100% - 66.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is 0.668. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.654. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.668TTM0.654+0.014
TTM0.654YOY0.623+0.030
TTM0.6545Y0.603+0.051
5Y0.60310Y0.627-0.024
1.4.2. Debt to Equity Ratio

Measures if Rekah is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 201.1% means that company has 2.01 debt for each 1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The MRQ is 2.011. The company is just not able to pay all its debts with equity.
  • The TTM is 1.895. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.011TTM1.895+0.115
TTM1.895YOY1.659+0.237
TTM1.8955Y1.543+0.353
5Y1.54310Y1.792-0.250

2. Market Valuation of Rekah Pharmaceutical Industry Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every 1 in earnings Rekah generates.

  • Above 15 is considered overpriced but always compare Rekah to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -9.29 means the investor is paying -9.29 for every 1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The EOD is -7.104. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.292. Based on the earnings, the company is expensive. -2
  • The TTM is 25.216. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD-7.104MRQ-9.292+2.188
MRQ-9.292TTM25.216-34.508
TTM25.216YOY41.525-16.309
TTM25.2165Y78.371-53.154
5Y78.37110Y50.753+27.618
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The EOD is -3.361. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.396. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.559. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.361MRQ-4.396+1.035
MRQ-4.396TTM-2.559-1.837
TTM-2.559YOY5.212-7.770
TTM-2.5595Y0.565-3.123
5Y0.56510Y0.282+0.282
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rekah is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Rekah Pharmaceutical Industry Ltd:

  • The EOD is 99.728. Based on the equity, the company is expensive. -2
  • The MRQ is 130.441. Based on the equity, the company is expensive. -2
  • The TTM is 115.803. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD99.728MRQ130.441-30.714
MRQ130.441TTM115.803+14.638
TTM115.803YOY145.449-29.646
TTM115.8035Y152.435-36.632
5Y152.43510Y190.134-37.699
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Rekah Pharmaceutical Industry Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.471-0.173-63%-0.116-75%0.024-2096%0.173-372%
Book Value Per Share--13.70714.088-3%14.571-6%14.132-3%11.892+15%
Current Ratio--1.6841.741-3%2.031-17%2.067-19%1.528+10%
Debt To Asset Ratio--0.6680.654+2%0.623+7%0.603+11%0.627+7%
Debt To Equity Ratio--2.0111.895+6%1.659+21%1.543+30%1.792+12%
Dividend Per Share----0%65.705-100%17.521-100%8.761-100%
Eps---48.105-11.897-75%8.115-693%7.296-759%-0.565-99%
Free Cash Flow Per Share---101.69457.286-278%53.869-289%27.221-474%27.221-474%
Free Cash Flow To Equity Per Share---101.69432.977-408%-11.836-88%18.440-651%18.440-651%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.850+18%
Intrinsic Value_10Y_max--8454.127--------
Intrinsic Value_10Y_min--7080.532--------
Intrinsic Value_1Y_max--273.390--------
Intrinsic Value_1Y_min--268.198--------
Intrinsic Value_3Y_max--1258.707--------
Intrinsic Value_3Y_min--1192.838--------
Intrinsic Value_5Y_max--2771.223--------
Intrinsic Value_5Y_min--2534.541--------
Market Cap15603758200.000-31%20409369168.00018600149362.000+10%24207589297.000-16%24546586292.200-17%24839283848.100-18%
Net Profit Margin---0.069-0.027-61%0.012-656%0.012-670%0.000-15517%
Operating Margin---0.017-100%0.051-100%0.071-100%0.047-100%
Operating Ratio--1.7861.720+4%1.670+7%1.677+6%1.313+36%
Pb Ratio99.728-31%130.441115.803+13%145.449-10%152.435-14%190.134-31%
Pe Ratio-7.104+24%-9.29225.216-137%41.525-122%78.371-112%50.753-118%
Price Per Share1367.000-31%1788.0001629.500+10%2120.750-16%2150.450-17%2176.095-18%
Price To Free Cash Flow Ratio-3.361+24%-4.396-2.559-42%5.212-184%0.565-879%0.282-1657%
Price To Total Gains Ratio-2899.797+24%-3792.858-1716.336-55%8415.056-145%6381.014-159%6062.057-163%
Quick Ratio--0.8310.891-7%1.031-19%0.933-11%0.975-15%
Return On Assets---1.166-0.450-61%0.213-649%0.188-720%0.009-12987%
Return On Equity---3.511-1.333-62%0.538-752%0.413-950%-0.048-99%
Total Gains Per Share---0.471-0.173-63%65.589-101%17.545-103%8.934-105%
Usd Book Value--425582.080437395.040-3%452382.920-6%438758.304-3%369228.848+15%
Usd Book Value Change Per Share---0.0010.000-63%0.000-75%0.000-2096%0.000-372%
Usd Book Value Per Share--0.0370.038-3%0.040-6%0.038-3%0.032+15%
Usd Dividend Per Share----0%0.179-100%0.048-100%0.024-100%
Usd Eps---0.131-0.032-75%0.022-693%0.020-759%-0.002-99%
Usd Free Cash Flow---3157376.0001778608.000-278%1672528.000-289%633868.800-598%316934.400-1096%
Usd Free Cash Flow Per Share---0.2770.156-278%0.147-289%0.074-474%0.074-474%
Usd Free Cash Flow To Equity Per Share---0.2770.090-408%-0.032-88%0.050-651%0.050-651%
Usd Market Cap42442222.304-31%55513484.13750592406.265+10%65844642.888-16%66766714.715-17%67562852.067-18%
Usd Price Per Share3.718-31%4.8634.432+10%5.768-16%5.849-17%5.919-18%
Usd Profit---1493552.000-573716.000-62%251940.000-693%185735.200-904%26764.800-5680%
Usd Revenue--21747760.00021439652.000+1%19510356.000+11%17810383.200+22%16855683.600+29%
Usd Total Gains Per Share---0.0010.000-63%0.178-101%0.048-103%0.024-105%
 EOD+3 -5MRQTTM+6 -27YOY+5 -305Y+5 -3010Y+10 -26

3.2. Fundamental Score

Let's check the fundamental score of Rekah Pharmaceutical Industry Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.104
Price to Book Ratio (EOD)Between0-199.728
Net Profit Margin (MRQ)Greater than0-0.069
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.831
Current Ratio (MRQ)Greater than11.684
Debt to Asset Ratio (MRQ)Less than10.668
Debt to Equity Ratio (MRQ)Less than12.011
Return on Equity (MRQ)Greater than0.15-3.511
Return on Assets (MRQ)Greater than0.05-1.166
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Rekah Pharmaceutical Industry Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.577
Ma 20Greater thanMa 501,414.450
Ma 50Greater thanMa 1001,440.520
Ma 100Greater thanMa 2001,484.430
OpenGreater thanClose1,340.000
Total0/5 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Operating Income  356,20040,600396,8009,300406,100-213,500192,600-345,600-153,000



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in ILA. All numbers in thousands.

Summary
Total Assets470,944
Total Liabilities314,480
Total Stockholder Equity156,415
 As reported
Total Liabilities 314,480
Total Stockholder Equity+ 156,415
Total Assets = 470,944

Assets

Total Assets470,944
Total Current Assets237,266
Long-term Assets233,678
Total Current Assets
Cash And Cash Equivalents 13,993
Short-term Investments 39
Net Receivables 117,027
Inventory 91,496
Total Current Assets  (as reported)237,266
Total Current Assets  (calculated)222,555
+/- 14,711
Long-term Assets
Property Plant Equipment 153,707
Long-term Assets  (as reported)233,678
Long-term Assets  (calculated)153,707
+/- 79,971

Liabilities & Shareholders' Equity

Total Current Liabilities140,863
Long-term Liabilities173,617
Total Stockholder Equity156,415
Total Current Liabilities
Short Long Term Debt 24,170
Accounts payable 77,117
Other Current Liabilities 16,467
Total Current Liabilities  (as reported)140,863
Total Current Liabilities  (calculated)117,754
+/- 23,109
Long-term Liabilities
Long term Debt 101,423
Capital Lease Obligations Min Short Term Debt43,567
Long-term Liabilities Other 19,703
Long-term Liabilities  (as reported)173,617
Long-term Liabilities  (calculated)164,693
+/- 8,924
Total Stockholder Equity
Retained Earnings 15,583
Total Stockholder Equity (as reported)156,415
Total Stockholder Equity (calculated)15,583
+/- 140,832
Other
Capital Stock13,641
Common Stock Shares Outstanding 11,415
Net Debt 111,600
Net Invested Capital 282,008
Net Working Capital 96,403
Property Plant and Equipment Gross 153,707



Balance Sheet

Currency in ILA. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-31
> Total Assets 
197,146
199,951
189,515
204,476
202,038
257,433
254,650
277,377
266,995
276,237
291,890
297,730
296,531
305,313
302,632
306,899
300,961
316,813
308,889
305,112
290,498
278,569
272,207
281,338
278,400
273,284
281,378
278,956
287,966
281,797
281,552
289,200
286,986
283,439
293,874
284,473
298,069
291,036
296,675
296,417
303,160
330,650
319,212
319,180
310,113
302,593
326,274
324,423
323,825
339,328
328,114
330,339
322,724
319,490
301,354
294,022
294,953
324,807
308,034
299,354
300,281
347,602
329,557
348,262
367,111
391,829
398,675
418,877
419,689
411,390
416,003
441,740
437,090
436,940
450,335
442,751
448,418
446,355
495,533
470,944
470,944495,533446,355448,418442,751450,335436,940437,090441,740416,003411,390419,689418,877398,675391,829367,111348,262329,557347,602300,281299,354308,034324,807294,953294,022301,354319,490322,724330,339328,114339,328323,825324,423326,274302,593310,113319,180319,212330,650303,160296,417296,675291,036298,069284,473293,874283,439286,986289,200281,552281,797287,966278,956281,378273,284278,400281,338272,207278,569290,498305,112308,889316,813300,961306,899302,632305,313296,531297,730291,890276,237266,995277,377254,650257,433202,038204,476189,515199,951197,146
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
226,988
223,471
205,477
195,781
192,396
222,850
205,995
198,236
197,146
225,325
202,202
184,784
177,682
197,908
204,468
226,191
227,353
218,014
223,927
220,975
221,660
220,690
235,848
233,064
243,141
251,571
260,854
237,266
237,266260,854251,571243,141233,064235,848220,690221,660220,975223,927218,014227,353226,191204,468197,908177,682184,784202,202225,325197,146198,236205,995222,850192,396195,781205,477223,471226,9880000000000000000000000000000000000000000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,668
30,047
23,884
24,693
24,989
37,174
22,629
25,529
31,692
63,393
38,848
14,653
25,568
45,197
40,914
33,384
36,893
38,515
37,886
21,808
18,603
21,605
31,521
13,541
20,208
21,700
24,732
13,993
13,99324,73221,70020,20813,54131,52121,60518,60321,80837,88638,51536,89333,38440,91445,19725,56814,65338,84863,39331,69225,52922,62937,17424,98924,69323,88430,04731,6680000000000000000000000000000000000000000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
0
0
45
45
45
0
40
40
41
40
40
40
40
40
40
40
39
39
39
87
88
80
39
36
39
3936398088873939394040404040404041404004545450031000000000000000000000000000000000000000000000000000000
       Net Receivables 
64,728
72,704
63,750
77,809
65,783
74,537
67,843
73,231
69,014
78,449
85,472
90,511
85,216
97,894
88,697
95,701
88,609
95,786
84,698
90,483
87,316
91,491
83,565
88,652
82,877
88,120
0
91,975
85,228
95,349
93,718
99,317
87,704
92,764
96,232
91,182
97,161
103,523
108,200
107,449
98,011
108,544
113,228
106,110
101,398
103,305
100,829
103,931
105,608
114,611
105,657
106,912
93,506
91,728
91,170
92,378
87,899
102,092
95,792
87,513
76,877
76,339
77,073
90,583
80,375
90,979
81,318
96,916
89,611
87,101
96,527
103,124
109,620
112,111
117,958
123,088
122,551
132,859
135,477
117,027
117,027135,477132,859122,551123,088117,958112,111109,620103,12496,52787,10189,61196,91681,31890,97980,37590,58377,07376,33976,87787,51395,792102,09287,89992,37891,17091,72893,506106,912105,657114,611105,608103,931100,829103,305101,398106,110113,228108,54498,011107,449108,200103,52397,16191,18296,23292,76487,70499,31793,71895,34985,22891,975088,12082,87788,65283,56591,49187,31690,48384,69895,78688,60995,70188,69797,89485,21690,51185,47278,44969,01473,23167,84374,53765,78377,80963,75072,70464,728
       Other Current Assets 
4,533
0
0
0
3,669
0
0
0
4,167
0
0
0
5,960
0
0
0
3,135
0
0
0
4,200
0
0
0
5,967
0
205,740
0
2,355
0
0
0
6,777
0
0
0
4,092
0
0
0
2,403
0
0
0
3,205
0
0
0
4,764
0
0
0
23,075
17,941
13,129
0
1,796
0
0
0
3,143
0
6,185
6,266
1,770
0
0
0
2,252
0
0
0
2,368
0
0
0
0
5,619
5,619
0
05,6195,61900002,3680002,2520001,7706,2666,18503,1430001,796013,12917,94123,0750004,7640003,2050002,4030004,0920006,7770002,3550205,74005,9670004,2000003,1350005,9600004,1670003,6690004,533
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
122,277
127,355
163,478
189,429
193,921
194,207
192,686
192,336
193,376
192,076
220,765
215,430
216,250
214,487
209,687
205,277
194,784
234,679
233,678
233,678234,679194,784205,277209,687214,487216,250215,430220,765192,076193,376192,336192,686194,207193,921189,429163,478127,355122,2770000000000000000000000000000000000000000000000000000000000000
       Property Plant Equipment 
44,397
43,943
42,737
42,596
43,026
43,506
44,407
44,647
44,624
44,076
44,358
58,206
58,031
58,194
57,530
57,311
56,239
56,290
57,728
59,121
61,482
61,810
61,937
62,267
66,744
68,177
0
68,519
68,308
68,197
68,712
68,451
68,822
72,388
73,227
73,378
72,302
71,653
70,576
69,569
69,894
70,564
73,212
77,195
82,052
82,784
84,268
84,017
86,401
86,878
86,810
87,541
88,555
88,818
89,763
92,469
96,281
96,380
96,376
95,564
97,430
116,646
122,857
158,182
181,023
183,939
183,392
181,928
181,818
182,740
181,020
180,912
177,003
172,520
171,228
167,354
163,206
153,566
153,372
153,707
153,707153,372153,566163,206167,354171,228172,520177,003180,912181,020182,740181,818181,928183,392183,939181,023158,182122,857116,64697,43095,56496,37696,38096,28192,46989,76388,81888,55587,54186,81086,87886,40184,01784,26882,78482,05277,19573,21270,56469,89469,56970,57671,65372,30273,37873,22772,38868,82268,45168,71268,19768,30868,519068,17766,74462,26761,93761,81061,48259,12157,72856,29056,23957,31157,53058,19458,03158,20644,35844,07644,62444,64744,40743,50643,02642,59642,73743,94344,397
       Goodwill 
2,830
0
0
0
2,267
0
0
0
1,705
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
1,500
0
0
0
0
0
0
0
1,340
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000001,34000000001,5000001,5000001,5000001,5000001,5000001,5000001,5000001,5000001,5000001,7050002,2670002,830
       Intangible Assets 
4,390
0
0
0
3,302
0
0
0
2,222
0
0
0
3,345
0
0
0
3,892
0
0
0
4,722
4,565
4,441
4,289
4,169
3,997
0
3,682
3,511
3,420
3,305
3,191
3,077
3,015
2,956
2,900
4,213
4,367
4,285
4,212
4,111
4,095
3,965
3,758
2,870
2,699
2,564
2,498
1,038
945
852
2,778
2,597
2,529
2,462
2,394
2,326
2,258
2,231
2,219
2,211
2,145
908
1,704
2,438
0
0
0
4,178
0
0
0
32,967
0
0
0
35,846
0
0
0
00035,84600032,9670004,1780002,4381,7049082,1452,2112,2192,2312,2582,3262,3942,4622,5292,5972,7788529451,0382,4982,5642,6992,8703,7583,9654,0954,1114,2124,2854,3674,2132,9002,9563,0153,0773,1913,3053,4203,5113,68203,9974,1694,2894,4414,5654,7220003,8920003,3450002,2220003,3020004,390
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
122,277
127,355
163,478
189,429
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000189,429163,478127,355122,2770000000000000000000000000000000000000000000000000000000000000
> Total Liabilities 
157,325
156,802
145,286
157,005
153,176
202,334
197,794
218,074
208,148
218,204
232,572
236,946
234,994
241,025
239,467
243,533
233,864
248,776
243,759
245,581
231,873
216,309
207,967
218,954
214,246
207,676
217,276
215,357
224,183
217,139
216,153
224,803
222,982
214,706
223,937
213,710
226,903
217,703
221,426
219,008
223,647
249,209
237,479
236,034
233,054
226,399
200,648
197,310
200,167
215,146
202,980
205,837
216,864
223,804
208,674
206,584
150,328
177,523
158,307
148,283
149,623
195,826
177,013
194,283
211,894
233,970
238,815
255,460
254,098
243,592
246,688
272,087
264,025
272,835
286,588
278,399
286,338
283,516
333,688
314,480
314,480333,688283,516286,338278,399286,588272,835264,025272,087246,688243,592254,098255,460238,815233,970211,894194,283177,013195,826149,623148,283158,307177,523150,328206,584208,674223,804216,864205,837202,980215,146200,167197,310200,648226,399233,054236,034237,479249,209223,647219,008221,426217,703226,903213,710223,937214,706222,982224,803216,153217,139224,183215,357217,276207,676214,246218,954207,967216,309231,873245,581243,759248,776233,864243,533239,467241,025234,994236,946232,572218,204208,148218,074197,794202,334153,176157,005145,286156,802157,325
   > Total Current Liabilities 
141,580
136,698
117,820
124,983
95,993
82,101
81,635
104,438
96,753
103,058
119,484
119,500
122,768
144,138
125,947
131,968
120,209
129,914
109,409
115,181
114,161
123,148
123,729
133,607
133,174
141,084
151,226
150,664
153,396
152,259
156,225
168,017
168,143
167,132
193,401
183,018
198,066
189,526
195,139
195,246
201,677
161,285
128,788
130,765
131,685
126,466
89,701
86,404
92,446
89,912
91,204
89,862
93,141
92,271
85,929
75,098
77,966
87,328
87,091
78,778
79,849
93,738
89,362
90,893
84,683
88,099
105,650
108,037
108,259
105,967
92,246
103,676
98,611
115,190
118,607
118,138
139,027
131,097
161,734
140,863
140,863161,734131,097139,027118,138118,607115,19098,611103,67692,246105,967108,259108,037105,65088,09984,68390,89389,36293,73879,84978,77887,09187,32877,96675,09885,92992,27193,14189,86291,20489,91292,44686,40489,701126,466131,685130,765128,788161,285201,677195,246195,139189,526198,066183,018193,401167,132168,143168,017156,225152,259153,396150,664151,226141,084133,174133,607123,729123,148114,161115,181109,409129,914120,209131,968125,947144,138122,768119,500119,484103,05896,753104,43881,63582,10195,993124,983117,820136,698141,580
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,079
94,158
81,265
14,045
14,054
11,219
11,240
11,264
21,790
27,201
20,264
22,102
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000022,10220,26427,20121,79011,26411,24011,21914,05414,04581,26594,15895,0790000000000000000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,079
94,158
81,265
14,045
14,054
11,219
11,240
11,264
21,790
27,201
20,264
22,102
20,616
23,118
22,938
27,454
27,057
25,369
15,491
24,965
18,967
19,468
19,480
20,003
19,575
20,439
25,472
24,170
24,17025,47220,43919,57520,00319,48019,46818,96724,96515,49125,36927,05727,45422,93823,11820,61622,10220,26427,20121,79011,26411,24011,21914,05414,04581,26594,15895,0790000000000000000000000000000000000000000000000000000
       Accounts payable 
36,630
43,167
37,696
48,368
46,025
50,381
48,609
51,814
45,340
47,646
54,046
52,949
48,118
55,318
53,363
51,440
45,492
47,502
41,622
48,230
38,769
41,764
42,024
53,964
45,899
50,937
0
45,677
48,213
51,975
50,767
57,205
53,086
59,273
63,373
58,714
66,738
65,222
66,610
63,647
63,566
67,554
66,970
68,958
58,393
60,976
61,846
56,780
63,366
58,627
62,057
61,373
49,295
50,052
45,047
49,956
51,228
57,141
54,948
42,108
46,845
51,755
51,499
49,777
47,025
48,775
66,370
64,882
59,885
64,038
60,176
60,128
57,442
68,425
80,941
81,338
88,114
79,883
100,655
77,117
77,117100,65579,88388,11481,33880,94168,42557,44260,12860,17664,03859,88564,88266,37048,77547,02549,77751,49951,75546,84542,10854,94857,14151,22849,95645,04750,05249,29561,37362,05758,62763,36656,78061,84660,97658,39368,95866,97067,55463,56663,64766,61065,22266,73858,71463,37359,27353,08657,20550,76751,97548,21345,677050,93745,89953,96442,02441,76438,76948,23041,62247,50245,49251,44053,36355,31848,11852,94954,04647,64645,34051,81448,60950,38146,02548,36837,69643,16736,630
       Other Current Liabilities 
17,515
18,090
16,425
16,878
14,971
16,186
17,786
17,555
16,785
17,521
14,902
12,804
13,376
14,611
13,809
12,217
14,147
10,532
11,526
11,267
11,967
10,826
11,305
10,830
13,816
11,659
151,226
10,845
14,363
12,739
11,453
10,529
12,797
11,754
11,886
11,462
13,546
10,200
11,270
10,854
13,559
12,287
12,361
12,821
11,586
11,850
10,937
11,365
12,723
13,553
11,352
11,544
28,782
27,783
26,860
11,097
12,679
11,726
10,662
12,121
2,784
10,616
13,900
13,908
6,801
11,465
11,556
10,870
3,538
11,902
11,910
13,473
3,556
22,342
12,903
11,435
11,322
25,352
18,201
16,467
16,46718,20125,35211,32211,43512,90322,3423,55613,47311,91011,9023,53810,87011,55611,4656,80113,90813,90010,6162,78412,12110,66211,72612,67911,09726,86027,78328,78211,54411,35213,55312,72311,36510,93711,85011,58612,82112,36112,28713,55910,85411,27010,20013,54611,46211,88611,75412,79710,52911,45312,73914,36310,845151,22611,65913,81610,83011,30510,82611,96711,26711,52610,53214,14712,21713,80914,61113,37612,80414,90217,52116,78517,55517,78616,18614,97116,87816,42518,09017,515
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
102,088
87,651
103,390
127,211
145,871
133,165
147,423
145,839
137,625
154,442
168,411
165,414
157,645
167,981
160,261
147,311
152,419
171,954
173,617
173,617171,954152,419147,311160,261167,981157,645165,414168,411154,442137,625145,839147,423133,165145,871127,211103,39087,651102,0880000000000000000000000000000000000000000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-95,079
-94,158
-81,265
-14,045
-14,054
-11,219
-11,240
-11,264
-21,790
-10,326
-5,811
11,080
50,748
52,098
50,781
49,616
48,427
47,823
46,680
46,972
45,629
44,315
46,099
44,497
43,137
41,763
42,584
43,567
43,56742,58441,76343,13744,49746,09944,31545,62946,97246,68047,82348,42749,61650,78152,09850,74811,080-5,811-10,326-21,790-11,264-11,240-11,219-14,054-14,045-81,265-94,158-95,0790000000000000000000000000000000000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000
2,000
2,000
2,000
2,000
2,000
11,213
11,213
13,293
14,514
15,333
6,485
6,569
21,116
19,703
19,70321,1166,5696,48515,33314,51413,29311,21311,2132,0002,0002,0002,0002,0002,00000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
39,378
42,631
43,707
46,851
48,197
54,335
55,957
58,289
57,859
56,932
58,177
59,564
60,269
62,916
61,770
61,947
65,646
66,433
63,566
58,004
57,018
60,526
62,381
60,464
62,162
63,564
62,032
61,524
63,010
63,878
64,590
63,541
63,547
68,248
69,398
70,219
70,588
72,754
74,688
76,780
78,866
80,816
81,078
82,451
76,352
75,494
124,986
126,447
122,970
123,490
124,430
124,125
105,502
95,988
92,997
87,768
145,009
147,815
150,308
151,721
151,365
152,511
153,325
154,808
155,155
157,797
159,798
163,355
165,529
167,745
169,263
169,601
173,013
164,055
163,697
164,302
162,030
162,790
161,796
156,415
156,415161,796162,790162,030164,302163,697164,055173,013169,601169,263167,745165,529163,355159,798157,797155,155154,808153,325152,511151,365151,721150,308147,815145,00987,76892,99795,988105,502124,125124,430123,490122,970126,447124,98675,49476,35282,45181,07880,81678,86676,78074,68872,75470,58870,21969,39868,24863,54763,54164,59063,87863,01061,52462,03263,56462,16260,46462,38160,52657,01858,00463,56666,43365,64661,94761,77062,91660,26959,56458,17756,93257,85958,28955,95754,33548,19746,85143,70742,63139,378
   Common Stock
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
62,032
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
7,691
11,826
11,826
11,826
11,826
11,826
11,826
11,826
11,826
11,826
11,826
11,826
11,826
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
13,641
0
13,641
13,641
0
013,64113,641013,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64113,64111,82611,82611,82611,82611,82611,82611,82611,82611,82611,82611,82611,8267,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,69162,0327,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,6917,691
   Retained Earnings 
15,612
18,865
19,941
23,085
24,431
27,361
28,983
31,315
30,885
29,958
31,201
32,588
33,293
35,940
34,794
34,971
41,878
42,665
39,798
34,236
33,250
36,758
38,613
36,696
38,394
39,796
0
37,756
39,242
40,110
40,822
39,773
39,779
44,480
45,630
46,451
46,820
48,986
50,920
53,012
55,098
57,048
57,310
58,683
52,584
51,726
50,027
51,488
48,011
48,531
49,471
49,166
30,543
21,029
18,038
12,809
5,261
8,067
10,560
11,973
11,617
12,763
13,577
15,060
15,407
18,049
20,074
23,607
25,690
27,768
29,139
29,413
32,729
23,690
23,208
23,692
21,349
22,059
21,014
15,583
15,58321,01422,05921,34923,69223,20823,69032,72929,41329,13927,76825,69023,60720,07418,04915,40715,06013,57712,76311,61711,97310,5608,0675,26112,80918,03821,02930,54349,16649,47148,53148,01151,48850,02751,72652,58458,68357,31057,04855,09853,01250,92048,98646,82046,45145,63044,48039,77939,77340,82240,11039,24237,756039,79638,39436,69638,61336,75833,25034,23639,79842,66541,87834,97134,79435,94033,29332,58831,20129,95830,88531,31528,98327,36124,43123,08519,94118,86515,612
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-5050-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505-505
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-24
0
91
229
376
440
536
617
741
862
933
983
1,034
0
01,034983933862741617536440376229910-24000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in ILA. All numbers in thousands.




Cash Flow

Currency in ILS. All numbers in thousands.




Income Statement

Currency in ILS. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue315,289
Cost of Revenue-235,631
Gross Profit79,65879,658
 
Operating Income (+$)
Gross Profit79,658
Operating Expense-306,864
Operating Income8,425-227,206
 
Operating Expense (+$)
Research Development3,658
Selling General Administrative19,887
Selling And Marketing Expenses-
Operating Expense306,86423,545
 
Net Interest Income (+$)
Interest Income275
Interest Expense-7,615
Other Finance Cost-826
Net Interest Income-8,166
 
Pretax Income (+$)
Operating Income8,425
Net Interest Income-8,166
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-6,6458,425
EBIT - interestExpense = -7,615
-8,437
-822
Interest Expense7,615
Earnings Before Interest and Taxes (EBIT)-970
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-6,645
Tax Provision-1,793
Net Income From Continuing Ops-8,438-8,438
Net Income-8,437
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-8,166
 

Technical Analysis of Rekah
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rekah. The general trend of Rekah is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rekah's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rekah Pharmaceutical Industry Ltd.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1,479 < 1,507 < 1,507.

The bearish price targets are: 1,326.

Tweet this
Rekah Pharmaceutical Industry Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rekah Pharmaceutical Industry Ltd. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rekah Pharmaceutical Industry Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rekah Pharmaceutical Industry Ltd. The current macd is -11.2761621.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rekah price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Rekah. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Rekah price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Rekah Pharmaceutical Industry Ltd Daily Moving Average Convergence/Divergence (MACD) ChartRekah Pharmaceutical Industry Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rekah Pharmaceutical Industry Ltd. The current adx is 21.74.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Rekah shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Rekah Pharmaceutical Industry Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rekah Pharmaceutical Industry Ltd. The current sar is 1,476.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Rekah Pharmaceutical Industry Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rekah Pharmaceutical Industry Ltd. The current rsi is 42.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Rekah Pharmaceutical Industry Ltd Daily Relative Strength Index (RSI) ChartRekah Pharmaceutical Industry Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rekah Pharmaceutical Industry Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rekah price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Rekah Pharmaceutical Industry Ltd Daily Stochastic Oscillator ChartRekah Pharmaceutical Industry Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rekah Pharmaceutical Industry Ltd. The current cci is -201.42743854.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Rekah Pharmaceutical Industry Ltd Daily Commodity Channel Index (CCI) ChartRekah Pharmaceutical Industry Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rekah Pharmaceutical Industry Ltd. The current cmo is -21.65409621.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Rekah Pharmaceutical Industry Ltd Daily Chande Momentum Oscillator (CMO) ChartRekah Pharmaceutical Industry Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rekah Pharmaceutical Industry Ltd. The current willr is -67.46987952.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Rekah is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Rekah Pharmaceutical Industry Ltd Daily Williams %R ChartRekah Pharmaceutical Industry Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rekah Pharmaceutical Industry Ltd.

Rekah Pharmaceutical Industry Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rekah Pharmaceutical Industry Ltd. The current atr is 63.56.

Rekah Pharmaceutical Industry Ltd Daily Average True Range (ATR) ChartRekah Pharmaceutical Industry Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rekah Pharmaceutical Industry Ltd. The current obv is 110,044.

Rekah Pharmaceutical Industry Ltd Daily On-Balance Volume (OBV) ChartRekah Pharmaceutical Industry Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rekah Pharmaceutical Industry Ltd. The current mfi is 13.44.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Rekah Pharmaceutical Industry Ltd Daily Money Flow Index (MFI) ChartRekah Pharmaceutical Industry Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rekah Pharmaceutical Industry Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-03STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-31STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-18MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Rekah Pharmaceutical Industry Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rekah Pharmaceutical Industry Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.577
Ma 20Greater thanMa 501,414.450
Ma 50Greater thanMa 1001,440.520
Ma 100Greater thanMa 2001,484.430
OpenGreater thanClose1,340.000
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Rekah with someone you think should read this too:
  • Are you bullish or bearish on Rekah? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rekah? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rekah Pharmaceutical Industry Ltd

I send you an email if I find something interesting about Rekah Pharmaceutical Industry Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Rekah Pharmaceutical Industry Ltd.

Receive notifications about Rekah Pharmaceutical Industry Ltd in your mailbox!